|
Athersys Inc
ATHX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Athersys Inc's sales fell
in III. Quarter 2023 from the same quarter a year ago.
Ranking at No. 3516
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.76 %
Athersys Inc net loss decreased from $-14 millions, to $-4 millions in III. Quarter 2023,
• More on ATHX's Growth
|
|
Athersys Inc realized a net loss in trailing twelve months.
Athersys Inc realized cash reduction of $ -0.51 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 4.19.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
• More on ATHX's Valuation
|
|
|
|
|
Athersys Inc realized net loss in trailing twelve months.
Athersys Inc realized cash outflow of $ -0.51per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 4.19.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
• More on ATHX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com